公开(公告)号：EP4209492A1

公开(公告)日：2023-07-12

申请号：EP21847386.6

申请日：2021-07-26

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences ,  Ruijin Hospital, Shanghai Jiaotong University School of Medicine ,  Suzhou Institute of Materia Medica China Science And Technology

发明人： LUO, Cheng ,  XI, Xiaodong ,  ZHOU, Bing ,  ZHU, Kongkai ,  MAO, Jianhua ,  LIU, Jingqiu ,  YANG, Yaxi ,  MEI, Lianghe ,  RUAN, Zheng ,  JIANG, Hao ,  XI, Wenda ,  LONG, Zhangbiao ,  XIAO, Bing ,  HUANG, Jiansong ,  JIANG, Hualiang

IPC分类号： C07D471/04 ,  C07D491/048 ,  C07D493/04 ,  C07D495/04 ,  C07D209/12 ,  C07D307/79 ,  C07D311/04 ,  C07D333/56 ,  A61K31/343 ,  A61K31/381 ,  A61K31/40 ,  A61K31/519 ,  A61P9/00

摘要： The present invention relates to a compound for treating thrombotic diseases. Specifically, the present invention provides a compound represented by formula I, or a pharmaceutically acceptable salt, or an enantiomer, or a diastereoisomer, or an atropisomer, or a racemate, or a polymorph, or a solvate, or an isotopically labeled derivative thereof. The compound disclosed in the present invention can be specifically combined with SH3 domain protein of Src kinase and then interfere the combination of integrin αIIbβ3 and Src kinase, so that outside-to-inside signal transduction is selectively inhibited and inside-to-outside signal transduction is not influenced; thus, while resisting thrombus, the compound of the present invention does not affect the normal physiological hemostatic function, prevents the occurrence of hemorrhagic side effect, and can be used as a new generation of effective medicine for preventing and treating thrombosis-related cardiovascular and cerebrovascular diseases.

公开(公告)号：EP3782995A1

公开(公告)日：2021-02-24

申请号：EP19788657.5

申请日：2019-04-18

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences ,  Suzhou Institute of Drug Innovation, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： ZHOU, Bing ,  LUO, Cheng ,  JIANG, Hualiang ,  YANG, Yaxi ,  MEI, Lianghe ,  LU, Wenchao ,  XIAO, Senhao ,  CHEN, Shijie ,  WAN, Shili ,  QIAO, Gang ,  ZHANG, Rukang

IPC分类号： C07D413/06 ,  C07D417/06 ,  C07D413/14 ,  A61K31/4725 ,  A61K31/55 ,  A61K31/553 ,  A61K31/554 ,  A61K31/5513 ,  A61P35/00 ,  A61P35/02 ,  A61P3/00 ,  A61P25/28 ,  A61P29/00

摘要： The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.